The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final overall survival results of a randomized phase III trial comparing weekly docetaxel plus cisplatin (DP) with 3-weekly docetaxel (D) monotherapy in elderly patients (pts) with advanced non-small-cell lung cancer (NSCLC): intergroup trial JCOG0803/WJOG4307L.
 
Koji Takeda
Honoraria - Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Mochida Pharmaceutical Co. Ltd.; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst)
 
Tetsuya Abe
No Relationships to Disclose
 
Yuichiro Ohe
No Relationships to Disclose
 
Shinzoh Kudoh
No Relationships to Disclose
 
Yukito Ichinose
Speakers' Bureau - Chugai Pharma; Kaken Pharmaceutical; Kyowa Hakko Kirin; Lilly Japan; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Taisho Toyama Pharma
Research Funding - Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Hiroaki Okamoto
Research Funding - Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Kyowa Hakko Kirin (Inst); Takeda (Inst)
 
Nobuyuki Yamamoto
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma
Consulting or Advisory Role - Boehringer Ingelheim
 
Hiroshige Yoshioka
Honoraria - Boehringer Ingelheim; Chugai Pharma; Lilly Japan
 
Koichi Minato
Research Funding - Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Toshiyuki Sawa
No Relationships to Disclose
 
Yasuo Iwamoto
No Relationships to Disclose
 
Hideo Saka
No Relationships to Disclose
 
Junki Mizusawa
Honoraria - Chugai Pharma
 
Tomonori Mizutani
No Relationships to Disclose
 
Shinichiro Nakamura
No Relationships to Disclose
 
Masahiko Ando
No Relationships to Disclose
 
Akira Yokoyama
No Relationships to Disclose
 
Kazuhiko Nakagawa
Honoraria - Bristol-Myers Squibb; Sanofi
 
Nagahiro Saijo
No Relationships to Disclose
 
Tomohide Tamura
Honoraria - Astellas Pharma; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly Japan; Novartis; OncoTherapy Science; Ono Pharmaceutical; Taiho Pharmaceutical